The Story of AffinityAI
AffinityAI was founded by three scientists with diverse backgrounds who have all experienced the challenges of obtaining high-quality antibodies with well-defined binding interfaces. To address these issues, we established AffinityAI to offer a streamlined service that eliminates the typical hardships, time delays, and high costs associated with traditional antibodies discovery. Instead, we provide cutting-edge AI-designed binders to accelerate your science.
The Management Team
Timothy P. Jenkins
CEO
Tim is now Assoc. Prof. and Head of Data Science at DTU Bioengineering. There he runs the Digital Biotechnology Lab - a world-leading protein binder laboratory encompassing over 30 members. His latest publications include a Nature article on the first in vivo success of AI protein therapeutics (together with Nobel Laureate David Baker), as well as a Nature Machine Intelligence article presenting a world leading protein sequencing tool.
Oliver Morell
CAIO
Trained in Timothy Jenkins' group at DTU and at the Institute for Protein Design at the University of Washington, Oliver has extensive experience in protein design. He now leads the ARCANE™ AI engine to deliver the Designerbodies™ you desire.
Esperanza Rivera-de-Torre
CTO
Esperanza is an Asst. Prof. at DTU Bioengineering and runs her own research group focused on protein expression and immunology. As such she has an impressive background in expressing complex proteins in a wide array of expression systems. Esperanza is in charge of our proprietary RAVEN™ platform.
Our Advisors
Thomas Binzer
Thomas Binzer is a seasoned executive with a strong track record in life science instrumentation, having led R&D, product management, and commercial strategy at Sophion Bioscience. With earlier leadership roles at Agilent and Thermo Fisher, he brings deep expertise in scientific marketing, diagnostics, and innovation management across global biotech markets.
Pia Thorbek
Pia is a seasoned pharmaceutical executive with over 28 years at Novo Nordisk, where she served as Corporate Vice President leading CMC development, protein formulation, and drug project management. Today, she advises early-stage life science ventures as a DeepTech mentor, drawing on her strategic and operational expertise in bringing biologics to market.
Andreas Hald
Andreas brings deep cross-sector expertise from both biotech startups and major pharmaceutical companies, including LEO Pharma, Zealand Pharma, Adcendo and Novo Nordisk, where he has worked with bioanalysis, translational biomarker assays and stretegy in early drug discovery.